SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
Amendment No. 9
U. S. Bioscience, Inc.
----------------------------
(Name of Issuer)
Common Stock par value $.005 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
911646 10 7
-----------------
(CUSIP Number)
William K. Hoskins, Esq. Donna J. Roberts, Esq.
General Counsel Secretary
Marion Merrell Dow Inc. The Dow Chemical Company
9300 Ward Parkway 2030 Dow Center
Kansas City, Missouri 64114 Midland, Michigan 48674
(816) 966-4000 (517) 636-1000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 3, 1995
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(4)(i)(A) or (B), check the
following box. [ ]
Check the following box if a fee is being paid with this statement [ ].
<PAGE> 2
CUSIP No. 911646 10 7
___________________________________________________________________________
1) Name of Reporting Person and its Marion Merrell Dow Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 2,210,770*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 2,210,770*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 2,210,770*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ X ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 5.42%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Excludes 424,480 shares owned by the Marion Merrell Dow Foundation as of
January 3, 1995, as to which the Reporting Person disclaims beneficial
ownership as previously set forth in Item 4(d).
<PAGE> 3
CUSIP No. 911646 10 7
___________________________________________________________________________
1) Name of Reporting Person and its The Dow Chemical Company
I.R.S. Identification Number 38-1285128
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 2,210,770*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 2,210,770*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 2,210,770*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ X ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 5.42%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Excludes 424,480 shares owned by the Marion Merrell Dow Foundation as of
January 3, 1995, as to which the Reporting Person disclaims beneficial
ownership as previously set forth in Item 4(d).
<PAGE> 4
Amendment No. 9
This Amendment No. 9 to the Statement on Schedule 13D (the "Statement")
relates to the shares of Common Stock, par value $.005 per share of U. S.
Bioscience, Inc. (the "Common Stock") owned by Marion Merrell Dow Inc., a
Delaware corporation ("MMDI"). This Amendment is filed on behalf of MMDI
and The Dow Chemical Company, a Delaware corporation ("Dow"). All
capitalized terms used in this Amendment and not otherwise defined herein
have the meanings ascribed to such terms in the Statement. This Amendment
is filed to reflect MMDI's disposition of 474,300 shares of the Common
Stock (a change of more than 1% of the total shares outstanding.)
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
MARION MERRELL DOW INC.
Date: January 5, 1995 By: /s/ Rebecca R. Tilden
-----------------------------------
Rebecca R. Tilden
Vice President, Assistant General
Counsel and Assistant Corporate
Secretary
<PAGE> 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
THE DOW CHEMICAL COMPANY
Date: January 5, 1995 By: /s/ Enrique C. Falla
------------------------------------
Enrique C. Falla
Executive Vice President and Chief
Financial Officer
